Seeing Is Believing
Currently out of the existing stock ratings of Robert Wasserman, 50 are a BUY (83.33%), 10 are a HOLD (16.67%).
Analyst Robert Wasserman, currently employed at BENCHMARK, carries an average stock price target met ratio of 22.05% that have a potential upside of 8.64% achieved within 31 days.
Robert Wasserman’s has documented 105 price targets and ratings displayed on 11 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on LGND, Ligand Pharmaceuticals orporated at 08-Nov-2024.
Analyst best performing recommendations are on EBS (EMERGENT BIOSOLUTIONS).
The best stock recommendation documented was for EBS (EMERGENT BIOSOLUTIONS) at 4/11/2024. The price target of $5 was fulfilled within 32 days with a profit of $2.81 (128.31%) receiving and performance score of 40.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$7
$5.04 (257.14%)
2 years 3 months 3 days ago
(18-Aug-2022)
0/1 (0%)
$2.29 (48.62%)
Which stock is Robert Wasserman is most bullish on?
Which stock is Robert Wasserman is most reserved on?
What Year was the first public recommendation made by Robert Wasserman?